Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stefan Proniuk
Observed name:
S. Proniuk
Institution:
Qurient (South Korea)
Observed institutions:
University of Arizona,
Arno Therapeutics (United States),
Qurient (South Korea)
OpenAlex ID:
A5034474315
Preformulation Study of Epigallocatechin Gallate, a Promising Antioxidant for Topical Skin Cancer Prevention
2002
·
Stefan Proniuk
, Bianca M. Liederer
, et al.
·
Journal of Pharmaceutical Sciences
·
81
AR‐12 Inhibits Multiple Chaperones Concomitant With Stimulating Autophagosome Formation Collectively Preventing Virus Replication
2016
·
Laurence Booth
, Jane L. Roberts
, et al.
·
Journal of Cellular Physiology
·
53
PDF
Effect of Temperature and Light on the Stability of Latanoprost and its Clinical Relevance
2001
·
Parham V. Morgan
, Stefan Proniuk
, et al.
·
Journal of Glaucoma
·
52
Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function
2016
·
Laurence Booth
, Brian Shuch
, et al.
·
Oncotarget
·
50
PDF
Some Important Considerations in the Use of Cyclodextrins
1999
·
James Blanchard
, Stefan Proniuk
·
Pharmaceutical Research
·
33
The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions
2017
·
Basant A. Abdulrahman
, Dalia Abdelaziz
, et al.
·
Scientific Reports
·
32
PDF
Anhydrous Carbopol® Polymer Gels for the Topical Delivery of Oxygen/Water Sensitive Compounds
2002
·
Stefan Proniuk
, James Blanchard
·
Pharmaceutical Development and Technology
·
31
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers
2018
·
Paul H. Cottu
, Jacques Bonneterre
, et al.
·
PLoS ONE
·
27
PDF
Topical Formulation Studies with DEET (N,N‐Diethyl‐3‐methylbenzamide) and Cyclodextrins
2002
·
Stefan Proniuk
, Bianca M. Liederer
, et al.
·
Journal of Pharmaceutical Sciences
·
23
Investigation of the Utility of an In Vitro Release Test for Optimizing Semisolid Dosage Forms
2001
·
Stefan Proniuk
, Sarah E. Dixon
, et al.
·
Pharmaceutical Development and Technology
·
22
A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
2013
·
Joaquin Mateo
, Johann Sebastian De Bono
, et al.
·
Journal of Clinical Oncology
·
20
Trans-ungual Delivery of AR-12, a Novel Antifungal Drug
2017
·
Avadhesh Singh Kushwaha
, P. Sharma
, et al.
·
AAPS PharmSciTech
·
19
Influence of degree of substitution of cyclodextrins on their colligative properties in solution
2001
·
Stefan Proniuk
, James Blanchard
·
Journal of Pharmaceutical Sciences
·
18
A Simplified and Rapid High-Performance Liquid Chromatographic Assay for Ketoprofen in Isopropyl Myristate
1998
·
S. Proniuk
, S. Lerkpulsawad
, et al.
·
Journal of Chromatographic Science
·
12
Exploring the in vitro potential of celecoxib derivative AR-12 as an effective antiviral compound against four dengue virus serotypes
2017
·
Pouya Hassandarvish
, Adrian Oo
, et al.
·
Journal of Antimicrobial Chemotherapy
·
10
AR-12 Inhibits Chaperone Proteins Preventing Virus Replication and the Accumulation of Toxic Misfolded Proteins
2016
·
Laurence Booth
, Jane L Roberts
, et al.
·
Journal of Clinical & Cellular Immunology
·
8
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).
2024
·
Hao Xie
, Anthony B. El-Khoueiry
, et al.
·
Journal of Clinical Oncology
·
4
PDF
A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC).
2014
·
Joaquin Mateo
, Daniel Nava Rodrigues
, et al.
·
Journal of Clinical Oncology
·
4
Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status
2017
·
A. Jayaram
, K. Nowakowska
, et al.
·
Annals of Oncology
·
3
712TiP A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
2023
·
A. Alistar
, D. Mahalingam
, et al.
·
Annals of Oncology
·
1
PDF
Actr-40. Phase 2 Safety and Efficacy of Ar-67 (7-t-butyldimethylsiltyl-10-hydroxycamptothecin) in Patients With Recurrent Glioblastoma Multiforme (gbm) or Gliosarcoma
2019
·
Priya Kumthekar
, Jeffrey Raizer
, et al.
·
Neuro-Oncology
·
1
PDF
Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.
2017
·
Anuradha Jayaram
, Karolina Nowakowska
, et al.
·
Journal of Clinical Oncology
·
1
Abstract 4523: Population pharmacokinetic (PPK) modeling of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancers
2015
·
Keyvan Rezai
, Paul Cottu
, et al.
·
Cancer Research
·
1
Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort.
2015
·
Anuradha Jayaram
, Karolina Nowakowska
, et al.
·
Journal of Clinical Oncology
·
1
Abstract A009: Preclinical safety and efficacy QP101: A novel HER2-targeting dual payload ADC combining topoisomerase I (TOP1) and cyclin dependent kinase 7 (CDK7) inhibitors
2026
·
Kiyean Nam
, Hwankyu Kang
, et al.
·
Clinical Cancer Research
Show more works
View as search
Works count:
34
Citation count:
507
H-index:
13
I10-index:
15
Year
Topic
Type
